The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo
Open accessAbstract
Vaccination with in vitro transcribed RNA coding for tumor antigens is considered a promising approach for cancer immunotherapy and has already entered human clinical testing. One of the basic objectives for development of RNA as a drug is the optimization of immunobioavailability of the encoded antigen in vivo. By analyzing the effect of different synthetic 5' mRNA cap analogs on the kinetics of the encoded protein, we found that m(2)(7,2'-O)Gpp(S)pG (beta-S-ARCA) phosphorothioate caps, in particular the D1 diastereoisomer, profoundly enhance RNA stability and translational efficiency in immature but not mature dendritic cells. Moreover, in vivo delivery of the antigen as beta-S-ARCA(D1)-capped RNA species is superior for protein expression and for efficient priming and expansion of naïve antigen-specific T cells in mice. Our findings establish 5' mRNA cap analogs as yet another module for tuning immunopharmacological properties of recombinant antigen-encoding RNA for vaccination purposes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These strategies have yielded modest improvements in RNA stability10, 13–16, and thus alternative approaches to RNA stabilization, such as circularization, are desirable.”
From Engineering circular RNA for potent and stable translation in eukaryotic cells (2018) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,486
Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological Targets
Sonenberg, N., & Hinnebusch, A. G. (2009) · Cell · doi:10.1016/j.cell.2009.01.042 · Cited by 3,304
Holtkamp, S., Kreiter, S., Selmi, A., Simon, P., Koslowski, M., Huber, C., Türeci, O., & Sahin, U. (2006) · Blood · doi:10.1182/blood-2006-04-015024 · Cited by 625
Self-citationGilboa, E. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31205 · Cited by 589
Quantitating Protein Synthesis, Degradation, and Endogenous Antigen Processing
Princiotta, M. F., Finzi, D., Qian, S.-B., Gibbs, J., Schuchmann, S., Buttgereit, F., Bennink, J. R., & Yewdell, J. W. (2003) · Immunity · doi:10.1016/s1074-7613(03)00051-7 · Cited by 521
Yewdell, J. W., Antón, L. C., & Bennink, J. R. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.5.1823 · Cited by 450
Weide, B., Pascolo, S., Scheel, B., Derhovanessian, E., Pflugfelder, A., Eigentler, T. K., Pawelec, G., Hoerr, I., Rammensee, H.-G., & Garbe, C. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181a00068 · Cited by 378 · cited 1×
“9 In summary, our data reveal 5 0 mRNA cap analogs as a further structural feature to modify the stability and translational efficiency of in vitro transcribed RNA for pharmaceutical applications.”
BackgroundSu, Z., Dannull, J., Yang, B. K., Dahm, P., Coleman, D., Yancey, D., Sichi, S., Niedzwiecki, D., Boczkowski, D., Gilboa, E., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.6.3798 · Cited by 359
(2001) · PubMed Central · Cited by 342
Novel “anti-reverse” cap analogs with superior translational properties
Jemielity, J., Fowler, T. E., Zuberek, J., Stȩpiński, J., Lewdorowicz, M., Niedźwiecka-Kornaś, A., Stolarski, R., Darżynkiewicz, E., & Rhoads, R. E. (2003) · RNA · doi:10.1261/rna.5430403 · Cited by 263
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Self-citationmRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Self-citationSystemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Self-citationMutant MHC class II epitopes drive therapeutic immune responses to cancer
Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., et al. (2015) · Nature · doi:10.1038/nature14426 · Cited by 1,243
Self-citationEngineering circular RNA for potent and stable translation in eukaryotic cells
Wesselhoeft, R. A., Kowalski, P. S., & Anderson, D. G. (2018) · Nature Communications · doi:10.1038/s41467-018-05096-6 · Cited by 853
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 852
Developing mRNA-vaccine technologies
Schlake, T., Thess, A., Fotin-Mleczek, M., & Kallen, K.-J. (2012) · RNA Biology · doi:10.4161/rna.22269 · Cited by 622
Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601
Vogel, A. B., Lambert, L., Kinnear, E., Busse, D., Erbar, S., Reuter, K. C., Wicke, L., Perkovic, M., Beissert, T., Haas, H., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.017 · Cited by 501
Self-amplifying RNA vaccines for infectious diseases
Bloom, K., van den Berg, F., & Arbuthnot, P. (2021) · Gene Therapy · doi:10.1038/s41434-020-00204-y · Cited by 487
The challenge and prospect of mRNA therapeutics landscape
Weng, Y., Li, C., Yang, T., Hu, B., Zhang, M., Guo, S., Xiao, H., Liang, X.-J., & Huang, Y. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107534 · Cited by 417
mRNA therapeutics in cancer immunotherapy
Beck, J. D., Reidenbach, D., Salomon, N., Sahin, U., Türeci, Ö., Vormehr, M., & Kranz, L. M. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01348-0 · Cited by 385
Self-citationOrlandini von Niessen, A. G., Poleganov, M. A., Rechner, C., Plaschke, A., Kranz, L. M., Fesser, S., Diken, M., Löwer, M., Vallazza, B., Beissert, T., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.12.011 · Cited by 365
Self-citationmRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection
Xu, S., Yang, K., Li, R., & Zhang, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186582 · Cited by 368
Three decades of messenger RNA vaccine development
Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100766 · Cited by 342
Kreiter, S., Selmi, A., Diken, M., Koslowski, M., Britten, C. M., Huber, C., Türeci, Ö., & Sahin, U. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0699 · Cited by 309
Self-citationControlling timing and location in vaccines
Irvine, D. J., Aung, A., & Silva, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.019 · Cited by 255
Immunologic Basis of Vaccine Vectors
Liu, M. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.004 · Cited by 237
Mechanism of action of mRNA-based vaccines
Iavarone, C., O’hagan, D. T., Yu, D., Delahaye, N. F., & Ulmer, J. B. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1355245 · Cited by 234
Weissman, D. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.973859 · Cited by 228
Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives
Gómez-Aguado, I., Rodríguez-Castejón, J., Vicente-Pascual, M., Rodríguez‐Gascón, A., Solinís, M. Á., & del Pozo‐Rodríguez, A. (2020) · Nanomaterials · doi:10.3390/nano10020364 · Cited by 229
A trans-amplifying RNA vaccine strategy for induction of potent protective immunity
Beissert, T., Perkovic, M., Vogel, A., Erbar, S., Walzer, K. C., Hempel, T., Brill, S., Haefner, E., Becker, R., Türeci, Ö., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.09.009 · Cited by 212
Self-citationEmerging Technologies for Low‐Cost, Rapid Vaccine Manufacture
Kis, Z., Shattock, R. J., Shah, N., & Kontoravdi, C. (2018) · Biotechnology Journal · doi:10.1002/biot.201800376 · Cited by 214
Kwon, H., Kim, M., Seo, Y., Moon, Y. S., Lee, H. J., Lee, K., & Lee, H. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.11.034 · Cited by 208
Lipid-based mRNA vaccine delivery systems
Midoux, P., & Pichon, C. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2015.986104 · Cited by 213
Diken, M., Kreiter, S., Selmi, A., Britten, C. M., Huber, C. G., Türeci, Ö., & Şahin, U. (2011) · Gene Therapy · doi:10.1038/gt.2011.17 · Cited by 192
Self-citationRecent Advancement in mRNA Vaccine Development and Applications
Fayez, N. A., Nassar, M. S., Alshehri, A. A., Alnefaie, M. K., Almughem, F. A., Alshehri, B. Y., Alawad, A. O., & Tawfik, E. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071972 · Cited by 187
mRNA cancer vaccines: Advances, trends and challenges
He, Q., Gao, H., Tan, D., Zhang, H., & Wang, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.03.011 · Cited by 171
Phua, K. K. L., Leong, K. W., & Nair, S. K. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.12.029 · Cited by 159
mRNA vaccine in cancer therapy: Current advance and future outlook
Li, Y., Wang, M., Peng, X., Yang, Y., Chen, Q., Liu, J., She, Q., Tan, J., Lou, C., Liao, Z., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1384 · Cited by 158
Nanomedicine-Based Approaches for mRNA Delivery
Uchida, S., Perche, F., Pichon, C., & Cabral, H. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00618 · Cited by 139
Challenges and advances towards the rational design of mRNA vaccines
Pollard, C., Koker, S. D., Saelens, X., Vanham, G. L., & Grooten, J. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.09.002 · Cited by 138
mRNA as novel technology for passive immunotherapy
Schlake, T., Theß, A., Thran, M., & Jordan, I. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2935-4 · Cited by 135
Biomedical applications of mRNA nanomedicine
Xiong, Q., Lee, G. Y., Ding, J., Li, W., & Shi, J. (2018) · Nano Research · doi:10.1007/s12274-018-2146-1 · Cited by 125
Development and Delivery Systems of mRNA Vaccines
Liang, Y., Huang, L., & Liu, T. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.718753 · Cited by 130
mRNA therapeutics deliver a hopeful message
Zhong, Z., Cafferty, S. M., Combes, F., Huysmans, H., Temmerman, J. D., Gitsels, A., Vanrompay, D. C. G., Catani, J. P., & Sanders, N. N. (2018) · Nano Today · doi:10.1016/j.nantod.2018.10.005 · Cited by 124
Single-cell mRNA transfection studies: Delivery, kinetics and statistics by numbers
Leonhardt, C., Schwake, G., Stögbauer, T. R., Rappl, S., Kuhr, J.-T., Ligon, T. S., & Rädler, J. O. (2014) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2013.11.008 · Cited by 117
Kallen, K., & Theß, A. (2013) · Therapeutic Advances in Vaccines · doi:10.1177/2051013613508729 · Cited by 122
Malczyk, A. H., Kupke, A., Prüfer, S., Scheuplein, V., Hutzler, S., Kreuz, D., Beißert, T., Bauer, S., Hubich-Rau, S., Tondera, C., et al. (2015) · Journal of Virology · doi:10.1128/jvi.01815-15 · Cited by 118
Tumor vaccination using messenger RNA: prospects of a future therapy
Kreiter, S., Diken, M., Selmi, A., Türeci, Ö., & Şahin, U. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.03.007 · Cited by 120
Self-citationInclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model
Almåsbak, H., Walseng, E., Kristian, A., Myhre, M. R., Inderberg, E. M., Munthe, L. A., Andersen, J. T., WANG, M. Y., Kvalheim, G., Gaudernack, G., et al. (2015) · Gene Therapy · doi:10.1038/gt.2015.4 · Cited by 116
Machine Learning for Designing Next-Generation mRNA Therapeutics
Castillo-Hair, S. M., & Seelig, G. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00621 · Cited by 122
Grunwitz, C. R., Salomon, N., Vascotto, F., Selmi, A., Bukur, T., Diken, M., Kreiter, S., Türeci, Ö., & Şahin, U. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1629259 · Cited by 116
Self-citationNon-immunotherapy application of LNP-mRNA: Maximizing efficacy and safety
Vlatkovic, I. (2021) · Biomedicines · doi:10.3390/biomedicines9050530 · Cited by 112
Grabbe, S., Haas, H., Diken, M., Kranz, L. M., Langguth, P., & Şahin, U. (2016) · Nanomedicine · doi:10.2217/nnm-2016-0275 · Cited by 118
Self-citationAn overview of rational design of mRNA-based therapeutics and vaccines
To, K. K. W., & Cho, W. C. S. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1935859 · Cited by 110
Optimizing 5’UTRs for mRNA-delivered gene editing using deep learning
Castillo-Hair, S., Fedak, S., Wang, B., Linder, J., Havens, K., Certo, M., & Seelig, G. (2024) · Nature Communications · doi:10.1038/s41467-024-49508-2 · Cited by 98
Holstein, J. M., Anhäuser, L., & Rentmeister, A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201604107 · Cited by 97
Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics
Kang, D. D., Li, H., & Dong, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114961 · Cited by 100
The Pivotal Role of Chemical Modifications in mRNA Therapeutics
Liu, A., & Wang, X. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.901510 · Cited by 102
Wojtczak, B. A., Sikorski, P. J., Fac-Dabrowska, K., Nowicka, A. M., Warmiński, M., Kubacka, D., Nowak, E., Nowotny, M., Kowalska, J., & Jemielity, J. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b02597 · Cited by 95
Self-citationMoyo, N., Vogel, A. B., Buus, S., Erbar, S., Wee, E. G., Sahin, U., & Hanke, T. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.10.010 · Cited by 94
Chemical Modifications of mRNA Ends for Therapeutic Applications
Warminski, M., Mamot, A., Depaix, A., Kowalska, J., & Jemielity, J. (2023) · Accounts of Chemical Research · doi:10.1021/acs.accounts.3c00442 · Cited by 91
Self-citationRecent Advances in RNA Therapeutics and RNA Delivery Systems Based on Nanoparticles
Shin, H., Park, S. D., Yim, Y., Kim, J., Choi, C., Won, C., & Min, D. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800065 · Cited by 95
RNA chemistry and therapeutics
Wang, S., Weissman, D., & Dong, Y. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01237-x · Cited by 109
Synthetic modified messenger RNA for therapeutic applications
Gao, M., Zhang, Q., Feng, X.-H., & Liu, J. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.06.020 · Cited by 89
Hybrid Biopolymer and Lipid Nanoparticles with Improved Transfection Efficacy for mRNA
Siewert, C. D., Haas, H., Cornet, V., Nogueira, S. S., Nawroth, T., Uebbing, L., Ziller, A., Al-Gousous, J., Rădulescu, A., Schroer, M. A., et al. (2020) · Cells · doi:10.3390/cells9092034 · Cited by 92
Engineering Gene Therapy: Advances and Barriers
Shahryari, A., Burtscher, I., Nazari, Z., & Lickert, H. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100040 · Cited by 87
Beißert, T., Koste, L., Perković, M., Walzer, K. C., Erbar, S., Selmi, A., Diken, M., Kreiter, S., Türeci, Ö., & Şahin, U. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.121 · Cited by 81
Self-citationFLT3 Ligand Enhances the Cancer Therapeutic Potency of Naked RNA Vaccines
Kreiter, S., Diken, M., Selmi, A., Diekmann, J., Attig, S., Hüsemann, Y., Koslowski, M., Huber, C., Türeci, Ö., & Sahin, U. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0291 · Cited by 75
Self-citationViral and Synthetic RNA Vector Technologies and Applications
Schott, J. W., Morgan, M., Galla, M., & Schambach, A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.143 · Cited by 76
Recent Advances in Modified Cap Analogs: Synthesis, Biochemical Properties, and mRNA Based Vaccines
Shanmugasundaram, M., Senthilvelan, A., & Kore, A. R. (2022) · The Chemical Record · doi:10.1002/tcr.202200005 · Cited by 82
Potential Therapeutic Applications of Rna Cap Analogs
Ziemniak, M., Strenkowska, M., Kowalska, J., & Jemielity, J. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.96 · Cited by 76
Self-citationThe mRNA Vaccine Revolution: COVID-19 Has Launched the Future of Vaccinology
Ye, Z., Harmon, J., Ni, W., Li, Y., Wich, D., & Xu, Q. (2023) · ACS Nano · doi:10.1021/acsnano.2c12584 · Cited by 72
mRNA – A game changer in regenerative medicine, cell-based therapy and reprogramming strategies
Chabanovska, O., Galow, A.-M., David, R., & Lemcke, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114002 · Cited by 81
Vallazza, B., Petri, S., Poleganov, M. A., Eberle, F., Kuhn, A. N., & Şahin, U. (2015) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1288 · Cited by 73
Self-citationIn vitro evolution of enhanced RNA replicons for immunotherapy
Li, Y., Teague, B., Zhang, Y., Su, Z., Porter, E., Dobosh, B., Wagner, T., Irvine, D. J., & Weiss, R. (2019) · Scientific Reports · doi:10.1038/s41598-019-43422-0 · Cited by 71
Gene and cell therapy for cystic fibrosis: From bench to bedside
Conese, M., Ascenzioni, F., Boyd, A., Coutelle, C., Fino, I. D., Smedt, S. C. D., Rejman, J., Rosenecker, J., Schindelhauer, D., & Scholte, B. J. (2011) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(11)60017-9 · Cited by 71
Beck, J. D., Diken, M., Suchan, M., Streuber, M., Diken, E., KOLB, L. D., Allnoch, L., Vascotto, F., Peters, D., Beißert, T., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.013 · Cited by 72
Self-citationmRNA-based therapeutics–Advances and perspectives
Sergeeva, O. V., Koteliansky, V., & Zatsepin, T. S. (2016) · Biochemistry (Moscow) · doi:10.1134/s0006297916070075 · Cited by 74
Uebbing, L., Ziller, A., Siewert, C., Schroer, M. A., Blanchet, C. E., Svergun, D. I., Ramishetti, S., Peer, D., Şahin, U., Haas, H., et al. (2020) · Langmuir · doi:10.1021/acs.langmuir.0c02446 · Cited by 68
Bangel‐Ruland, N., Tomczak, K., Fernández, E. F., Leier, G., Leciejewski, B., Rudolph, C., Rosenecker, J., & Weber, W. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2748 · Cited by 67
Strzelecka, D., Śmietański, M., Sikorski, P. J., Warmiński, M., Kowalska, J., & Jemielity, J. (2020) · RNA · doi:10.1261/rna.077099.120 · Cited by 68
Self-citationBiological Therapies in the Treatment of Cancer—Update and New Directions
Papiez, M. A., & Krzyściak, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111694 · Cited by 72
Investigation of charge ratio variation in mRNA – DEAE-dextran polyplex delivery systems
Siewert, C., Haas, H., Nawroth, T., Ziller, A., Nogueira, S. S., Schroer, M. A., Blanchet, C. E., Svergun, D. I., Rădulescu, A., Bates, F., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.020 · Cited by 65
mRNA-Based Therapeutics in Cancer Treatment
Sun, H., Zhang, Y., Wang, G., Yang, W., & Xu, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020622 · Cited by 65
Strenkowska, M., Grzela, R., Majewski, M., Wnek, K., Kowalska, J., Łukaszewicz, M., Zuberek, J., Darżynkiewicz, E., Kuhn, A. N., Şahin, U., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw896 · Cited by 63
Self-citationEnabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing
Youssef, M., Hitti, C., Fulber, J. P. C., & Kamen, A. (2023) · Biomolecules · doi:10.3390/biom13101497 · Cited by 63
Su, W., Slepenkov, S. V., Slevin, M. K., Lyons, S. M., Ziemniak, M., Kowalska, J., Darżynkiewicz, E., Jemielity, J., Marzluff, W. F., & Rhoads, R. E. (2012) · RNA · doi:10.1261/rna.034470.112 · Cited by 60
Self-citationSynthetic mRNAs with Superior Translation and Stability Properties
Grudzien‐Nogalska, E., Kowalska, J., Su, W., Kuhn, A. N., Slepenkov, S. V., Darżynkiewicz, E., Şahin, U., Jemielity, J., & Rhoads, R. E. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-260-5_4 · Cited by 59
Self-citationRydzik, A. M., Kulis, M., Łukaszewicz, M., Kowalska, J., Zuberek, J., Darżynkiewicz, Z. M., Darżynkiewicz, E., & Jemielity, J. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.01.013 · Cited by 59
Self-citationKyte, J. A., Aamdal, S., Dueland, S., Sæbøe‐Larssen, S., Inderberg, E. M., Madsbu, U. E., Skovlund, E., Gaudernack, G., & Kvalheim, G. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1232237 · Cited by 59
Applications of Phosphate Modification and Labeling to Study (m)RNA Caps
Warmiński, M., Sikorski, P. J., Kowalska, J., & Jemielity, J. (2017) · Topics in Current Chemistry · doi:10.1007/s41061-017-0106-y · Cited by 57
Self-citationModified ARCA analogs providing enhanced translational properties of capped mRNAs
Kocmik, I., Piecyk, K., Rudzińska, M., Niedźwiecka-Kornaś, A., Darżynkiewicz, E., Grzela, R., & Jankowska‐Anyszka, M. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1486164 · Cited by 57
Kowalska, J., del Nogal, A. W., Darżynkiewicz, Z. M., Buck, J., Nicola, C., Kuhn, A. N., Łukaszewicz, M., Zuberek, J., Strenkowska, M., Ziemniak, M., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku757 · Cited by 56
Self-citationMessenger RNA vaccines for cancer immunotherapy: progress promotes promise
Huff, A. L., Jaffee, E. M., & Zaidi, N. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156211 · Cited by 60
Immunological Analysis of a CCHFV mRNA Vaccine Candidate in Mouse Models
Farzani, T. A., Földes, K., Ergünay, K., Gürdal, H., Baştuğ, A., & Özkul, A. (2019) · Vaccines · doi:10.3390/vaccines7030115 · Cited by 55
Induction of immunosuppressive functions and NF-κB by FLIP in monocytes
Fiore, A., Ugel, S., Sanctis, F. D., Sandri, S., Fracasso, G., Trovato, R., Sartoris, S., Solito, S., Mandruzzato, S., Vascotto, F., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07654-4 · Cited by 53
Design of in vitro Transcribed mRNA Vectors for Research and Therapy
Tusup, M., French, L. E., Matos, M. D., Gatfield, D., Kündig, T. M., & Pascolo, S. (2019) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2019.391 · Cited by 55
Therapeutic mRNA Engineering from Head to Tail
Jia, L., & Qian, S. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00541 · Cited by 51
Polysarcosine-Functionalized mRNA Lipid Nanoparticles Tailored for Immunotherapy
Wilhelmy, C., Keil, I. S., Uebbing, L., Schroer, M. A., Franke, D., Nawroth, T., Barz, M., Şahin, U., Haas, H., Diken, M., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082068 · Cited by 51
Self-citationAdvances in lipid nanoparticle mRNA therapeutics beyond COVID-19 vaccines
Wu, Y., Yu, S., & de Lázaro, I. (2024) · Nanoscale · doi:10.1039/d4nr00019f · Cited by 51
Sulfur modification in natural RNA and therapeutic oligonucleotides
Zheng, Y. Y., Wu, Y., Begley, T. J., & Sheng, J. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00038a · Cited by 52
Salomon, N., Vascotto, F., Selmi, A., Vormehr, M., Quinkhardt, J., Bukur, T., Schrörs, B., Löewer, M., Diken, M., Türeci, Ö., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1771925 · Cited by 49
Self-citationMilac, A. L., Bojarska, E., & del Nogal, A. W. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.04.007 · Cited by 46
mRNA Cancer Vaccines—Messages that Prevail
Grunwitz, C. R., & Kranz, L. M. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_509 · Cited by 47
Reductive Decationizable Block Copolymers for Stimuli-Responsive mRNA Delivery
Nuhn, L., Kaps, L., Diken, M., Schuppan, D., & Zentel, R. (2016) · Macromolecular Rapid Communications · doi:10.1002/marc.201600046 · Cited by 46
Self-citationEftekhari, Z., Zohrabi, H., Oghalaie, A., Ebrahimi, T., Shariati, F. S., Behdani, M., & Kazemi‐Lomedasht, F. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102313 · Cited by 46
Monitoring Translation Activity of mRNA-Loaded Nanoparticles in Mice
Rosigkeit, S., Meng, M., Grunwitz, C. R., Gomes, P., Kreft, A., Hayduk, N., Heck, R., Pickert, G., Ziegler, K., Abassi, Y., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00370 · Cited by 45
Self-citationScope and challenges of nanoparticle-based mRNA delivery in cancer treatment
Karim, M. E., Haque, S. T., Al-Busaidi, H., Bakhtiar, A., Tha, K. K., Holl, M. M. B., & Chowdhury, E. H. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01418-x · Cited by 45
Metadata
- Authors
- Kuhn, A. N., Diken, M., Kreiter, S., Selmi, A., Kowalska, J., Jemielity, J., Darzynkiewicz, E., Huber, C., Türeci, Ö., & Sahin, U.
- Affiliations
- Johannes Gutenberg University Mainz (DE)
- University of Warsaw (PL)
- Venue
- Gene Therapy
- Published
- 2010-04-22
- Volume
- 17
- Issue
- 8
- Pages
- 961-971
- ISSN
- 0969-7128 (ISSN-L)
- 1476-5462
- OpenAlex
- W2085865810
- Cited by
- 226
- References
- 32
- Citations by year
- 2026: 14 · 2025: 13 · 2024: 19 · 2023: 21 · 2022: 13 · 2021: 20 · 2020: 15 · 2019: 9 · 2018: 16 · 2017: 11 · 2016: 17 · 2015: 12 · 2014: 14 · 2013: 10 · 2012: 7
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gene Therapy (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute (55005604)
- Bundesministerium für Bildung und Forschung
- Ministerstwo Edukacji i Nauki
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Keywords
- mRNA vaccines, RNA stability, translation efficiency, immature dendritic cells, cancer immunotherapy, in vitro transcribed mRNA, immunopharmacology
- MeSH terms
- Dendritic Cells, Half-Life, Humans, Luciferases, RNA, RNA Cap Analogs, Protein Biosynthesis, Vaccines, Synthetic, Genes, Reporter, Antigen Presentation, Cancer Vaccines, RNA Stability, Phosphorothioate Oligonucleotides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
